scholarly journals Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema

2021 ◽  
Vol Volume 15 ◽  
pp. 4175-4180
Author(s):  
Alaa Dweikat ◽  
Arkan Jarrar ◽  
Mohammad Akkawi ◽  
Mohammad Shehadeh ◽  
Ammar Aghbar ◽  
...  
2018 ◽  
Vol 62 (3) ◽  
pp. 212-216 ◽  
Author(s):  
Ashraf Khorasani Maryam ◽  
Mohammadi Tafgeh ◽  
Motallebi Mahmoud ◽  
Anvari Pasha ◽  
Sedaghat Ahad ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Moon Young Choi ◽  
Jin-woo Kwon

Purpose. We identified the associations between levels of aqueous glucose-regulated protein 78 (GRP78) and systemic or ocular factors in patients with center-involving diabetic macular edema (CIDME). Methods. We measured the aqueous concentrations of GRP78, interleukin- (IL-) 1β, IL-2, IL-8, IL-10, and IL-17, placental growth factor, and vascular endothelial growth factor (VEGF). We explored the associations between aqueous GRP78 levels and those of other aqueous factors, optical coherence tomography (OCT) findings, and systemic parameters in CIDME patients. Results. In multivariate regression analysis, aqueous GRP78 levels were associated with aqueous VEGF levels (p=0.007), length of EZ disruption (p<0.001), and duration of diabetes (p=0.002). However, no significant relationship was observed between GRP78 levels and those of other systemic and ocular factors including inflammatory cytokines in the aqueous humor. In terms of responsiveness, the number of hyperreflective foci (≥8) was significantly associated with the responsiveness of three consecutive monthly intravitreal bevacizumab injections (OR=0.34, p=0.046), but not the aqueous GRP78 levels. Conclusions. Aqueous GRP78 levels correlated with VEGF levels in the aqueous humor and EZ disruption on OCT. However, GRP78 levels were not associated with those of inflammatory biomarkers in the aqueous humor or OCT findings. Additionally, GRP78 could not serve as a biomarker to predict short-term prognosis of anti-VEGF agent.


2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
A. Altun ◽  
A. M. Hacimustafaoglu

Aim. To investigate the change in subfoveal choroidal thickness (SFCT) in vitrectomized eyes with intravitreal dexamethasone (IVD) implant injection for the treatment of diabetic macular edema (DME). Method. In this prospective and controlled study, the vitrectomized eyes of diabetic patients were included. The study group (Group 1) was formed by diabetic vitrectomized eyes with DME. The control group (Group 2) was formed by diabetic vitrectomized eyes without DME. Only one intravitreal IVD implant was injected into the eyes in Group 1. In the first, second, and fourth months, choroidal layers were measured by optical coherence tomography and complete ophthalmologic examinations were performed for all cases. Results. Ninety-six eyes of 96 cases were included in the study. There were 48 eyes of 48 different patients in each group. After IVD injection, statistically significant improvement was observed in the best corrected visual acuity in Group 1. The mean SFCT in eyes with DME was statistically significantly thinner ( p  < 0.01) and thinness became more pronounced during the four-month follow-up period after IVD implant injection ( p  < 0.01). Conclusion. In the presence of DME in vitrectomized eyes, the thinness of the SFCT may become evident after dexamethasone implant injection.


Sign in / Sign up

Export Citation Format

Share Document